Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.68 USD | -1.08% | -3.92% | -11.11% |
03-19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
03-19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 20
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 12-05-30 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Charles Ence
CMP | Compliance Officer | 64 | 19-07-28 |
John Hixon
PRN | Corporate Officer/Principal | - | 22-07-20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 15-07-13 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Fabiana Fedeli
BRD | Director/Board Member | 53 | 23-01-11 |
Director/Board Member | 62 | 19-12-18 | |
Paul Kelly
BRD | Director/Board Member | 65 | 15-11-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 30,174,202 | 27,748,959 ( 91.96 %) | 0 | 91.96 % |
Company contact information
Relmada Therapeutics, Inc.
2222 Ponce de Leon Boulevard 3rd floor
33134, Coral Gables
+786-629-1376
http://www.relmada.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.11% | 111M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- RLMD Stock
- Company Relmada Therapeutics, Inc.